Hewlett Packard Enterprise Co vs 10X Genomics Inc — how do they compare? Hewlett Packard Enterprise Co trades at $56.99 (market cap $72.01B), while 10X Genomics Inc trades at $57.29 (market cap $7.61B). The key difference: Hewlett Packard Enterprise Co is far larger — about 9.5× 10X Genomics Inc's market cap, and Hewlett Packard Enterprise Co pays a 1.05% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| HPE | TXG | |
|---|---|---|
Market Cap | $72.01B | $7.61B |
Sector | Technology | Health |
52-Week High | $56.14 | $58.57 |
52-Week Low | $20.01 | $11.34 |
Enterprise Value | $87.96B | $7.14B |
Dividend Yield | 1.05% | — |
Signals from Pluang's Aura AI — not financial advice
HPE stock trades at $56.32, up 3.02% with strong momentum following recent analyst upgrades. The company shows robust earnings beats in recent quarters with Q1 2026 EPS of $0.79 beating expectations of $0.535. Technical indicators suggest bullish momentum while fundamentals show revenue growth to $34.3B in 2025, though net income declined significantly to $57M. Recent Morgan Stanley upgrade highlights AI infrastructure strength.
Outlook remains positive with AI-driven growth potential, though elevated P/E ratio of 50.82 warrants caution. Key risks include competitive pressures in server markets and execution challenges. Analyst consensus price target of $69.81 offers 24% upside potential from current levels, supported by institutional buying interest.
TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.
Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.
Trailing returns across standard periods
Latest headlines on both assets
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →